{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:52:08Z","timestamp":1791150728141,"version":"4.1.0"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T00:00:00Z","timestamp":1395360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This phase<jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>a study evaluated the safety and tolerability of sotatercept, and its effects on bone metabolism and haematopoiesis in newly diagnosed and relapsed multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) patients. Patients were randomized (4:1) to receive four 28\u2010d cycles of sotatercept (0\u00b71, 0\u00b73, or 0\u00b75\u00a0mg\/kg) or placebo. Patients also received six cycles of combination oral melphalan, prednisolone, and thalidomide (<jats:styled-content style=\"fixed-case\">MPT<\/jats:styled-content>). Thirty patients were enrolled; six received placebo and 24 received sotatercept. Overall, 25% of patients received all four sotatercept doses; 71% of sotatercept\u2010treated patients had \u22651 dose interruption mainly due to increases in haemoglobin levels. Grade \u22653 adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s) were reported in 17% of patients receiving placebo and 58% receiving sotatercept. Grade 4<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s in sotatercept\u2010treated patients were neutropenia, granulocytopenia, and atrial fibrillation (one patient each). In patients without bisphosphonate use, anabolic improvements in bone mineral density and in bone formation relative to placebo occurred, whereas bone resorption was minimally affected. Increases in haemoglobin levels,<jats:italic>versus<\/jats:italic>baseline, and the duration of the increases, were higher in the sotatercept\u2010treated patients, with a trend suggesting a dose\u2010related effect. Multiple doses of sotatercept plus<jats:styled-content style=\"fixed-case\">MPT<\/jats:styled-content>appear to be safe and generally well\u2010tolerated in<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>patients.<\/jats:p>","DOI":"10.1111\/bjh.12835","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T06:44:41Z","timestamp":1395384281000},"page":"814-823","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":122,"title":["Sotatercept in patients with osteolytic lesions of multiple myeloma"],"prefix":"10.1111","volume":"165","author":[{"given":"Kudrat M.","family":"Abdulkadyrov","sequence":"first","affiliation":[{"name":"Russian Research Institute of Haematology and Blood Transfusion St Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina N.","family":"Salogub","sequence":"additional","affiliation":[{"name":"St Petersburg Pavlov State Medical University n.a. I.P. Pavlov St Petersburg Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuriet K.","family":"Khuazheva","sequence":"additional","affiliation":[{"name":"Municipal Clinical Hospital n.a. S.P. Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Acceleron Pharma Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Laadem","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Barger","sequence":"additional","affiliation":[{"name":"Acceleron Pharma Inc. Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Knight","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"Department of Clinical Therapeutics University of Athens School of Medicine Alexandra General Hospital Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,21]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard N.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200310233491721"},{"issue":"6","key":"e_1_2_8_6_1","first-page":"133","article-title":"A soluble activin type II receptor prevents myeloma bone disease [Abstract]","volume":"92","author":"Chantry A.","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_8_7_1","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos M.A.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.09.018"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.19.1616"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2007.0017","article-title":"Multiple myeloma: most common end\u2010organ damage and management","volume":"5","author":"Hussein M.A.","year":"2007","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle R.A.","year":"1975","journal-title":"Mayo Clinical Proceedings"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.1269"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.150"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.01.370"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200160"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.11.001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70157-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711263105"},{"key":"e_1_2_8_21_1","first-page":"586","article-title":"Sotatercept, a soluble activin receptor type 2A IgG\u2010Fc fusion protein for the treatment of anemia and bone loss","volume":"5","author":"Raje N.","year":"2010","journal-title":"Current opinion in molecular therapeutics"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(96)00318-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.105"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081208"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/jcph.160","article-title":"Multiple\u2010dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA\u2010IgG1), a novel erythropoietic agent, in healthy postmenopausal women","volume":"11","author":"Sherman M.L.","year":"2013","journal-title":"The Journal of Clinical Pharmacology"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.5.1553"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10613"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396853"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.235"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.173"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq259"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.62"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds068"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23577"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2520.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911929107"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845412Y.0000000021"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12835","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.12835","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T03:44:39Z","timestamp":1746157479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,21]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/bjh.12835"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12835","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,21]]},"assertion":[{"value":"2013-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}